ArticleBMC women's health2026
Efficacy of FOXP3+Treg cells combined with platelet in predicting recurrence of cervical cancer: a retrospective study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundResearch on the impact of tumor-infiltrating immune cells(TIICs) combined with systemic inflammatory response (SIR) factors on cervical lesions and the prognosis of squamous cell cervical cancer (SCC) is limited. Therefore, this study aimed to evaluate the predictive and prognostic significance of TIICs and SIR factors in cervical epithelial lesions, specifically non-cervical epithelial lesions (NC), high-grade squamous intraepithelial lesions (HSIL), and SCC.
methodsThis retrospective study analyzed 163 patients in three cohorts: NC (n = 59), HSIL (n = 52), and SCC (n = 52). Tumor-infiltrating immune cells (TIICs) in the tumor/lesion center and adjacent stroma were assessed via immunohistochemistry and multiplex immunofluorescence, while systemic inflammatory response (SIR) factors were derived from preoperative blood counts. The primary outcome was relapse-free survival (RFS) in the SCC cohort, analyzed using Cox proportional hazards regression.
resultsTIICs were significantly elevated in the HSIL group compared with those in the NC group, accompanied by reduced platelet counts (PLT). The tumor stroma (TS) exhibited a greater degree of TIICs than the tumor/lesion center (TC) in both the HSIL and SCC groups. The presence of CD163+, CD11b+, and FOXP3 + TIICs, along with PLT levels, emerged as key indicators associated with the advanced histological stage. Compared to tTIICs, sTIICs demonstrated superior diagnostic performance in differentiating between HSIL and SCC groups. Lower levels of PLT (hazard ratio [HR] = 5.047, 95% confidence interval [CI]:1.373–18.540, P = 0.015), higher CD4 + T cells (HR = 0.211, 95%CI:0.062–0.722, P = 0.008), and FOXP3 + regulatory T cells (Tregs) (HR = 0.245, 95%CI:0.073–0.820, P = 0.010) were identified as poor prognostic indicators for recurrence-free survival (RFS) in SCC. A combination of FOXP3 + Tregs and PLT provided a more robust prediction of SCC recurrence. An increase in exhausted CD4 + T cells likely explains the observation that higher CD4 + T-cell infiltration correlated with lower RFS in SCC.
conclusionThe spatial distribution of TIICs, particularly the density in the tumor stroma, increases across the histological spectrum of cervical lesion severity. A signature combining FOXP3 + Treg cells and preoperative platelet counts provides a robust model for predicting SCC recurrence. Furthermore, the accumulation of exhausted CD4 + T cells appears to be a hallmark of disease advancement and poor prognosis, offering potential targets for personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.